Management of Allergic Rhinitis

Initial Assessment and Treatment

• The American Academy of Allergy, Asthma, and Immunology recommends that pharmacists distinguish allergic rhinitis from other conditions presenting with similar nasal symptoms, characterized by nasal itching, rhinorrhea, sneezing, and eye symptoms 1, 2, 3
• Allergic rhinitis is characterized by nasal itching, rhinorrhea, sneezing, and eye symptoms, while rhinosinusitis presents with nasal congestion, rhinorrhea, facial pain/pressure, and reduced sense of smell 1, 2, 3
• The presence of nasal itching and eye symptoms strongly suggests allergic rhinitis rather than other conditions 1, 2, 3

First-Line Pharmacotherapy

• The American College of Allergy, Asthma, and Immunology recommends intranasal corticosteroids as first-line therapy for patients with moderate to severe allergic rhinitis, due to their superior efficacy in overall symptom control 4, 5
• Intranasal corticosteroids are the most effective treatment and should be the first-line recommendation for moderate to severe allergic rhinitis, with examples including fluticasone, triamcinolone, budesonide, and mometasone 4, 5
• Patients must be counseled to direct sprays away from the nasal septum to prevent irritation and bleeding, and maximum efficacy may take several days of consistent use 6

Adjunctive Therapies

• The American Academy of Otolaryngology recommends oral decongestants for symptomatic relief, but with careful patient screening due to contraindications in patients with hypertension, anxiety, or cardiac conditions 7, 6
• Topical nasal decongestants must be limited to 3-5 days maximum to prevent rebound congestion (rhinitis medicamentosa) 7, 6
• Nasal saline irrigation is recommended as adjunctive non-pharmacological therapy to relieve congestion and facilitate clearance of nasal secretions 7, 5

Medications to Avoid

• The American Academy of Allergy, Asthma, and Immunology recommends avoiding antibiotics for allergic rhinitis, as they are ineffective for allergic conditions and contribute to antimicrobial resistance 7
• First-generation antihistamines should be avoided in most patients due to sedation, impaired work performance, and increased accident risk 8

Special Populations

• In children under 3 years, decongestants and antihistamines should be avoided due to the risk of adverse effects outweighing benefits 6
• In older adults, extreme caution should be exercised with first-generation antihistamines due to increased sensitivity to psychomotor impairment and anticholinergic effects 8

Patient Counseling

• Pharmacists should provide proactive interventions, including counseling on proper intranasal spray technique, consistent use of intranasal corticosteroids, and strict time limits for topical decongestants 1, 2, 6, 7
• Patients should be educated on signs requiring physician evaluation, including symptoms not adequately controlled with OTC pharmacotherapy, suspected complications, and uncertain diagnosis or atypical presentation 1, 2, 5

Allergic Rhinitis Management

Treatment Options

• Second-generation oral antihistamines or intranasal antihistamines are effective for sneezing, itching, and rhinorrhea in patients with mild intermittent symptoms, according to the American Academy of Allergy, Asthma, and Immunology 9, 10
• For seasonal allergic rhinitis, starting medication before the season begins is recommended for optimal prophylaxis, as suggested by the American College of Allergy, Asthma, and Immunology 9, 10

Environmental Control Measures

• Identifying specific allergens through testing and implementing targeted avoidance strategies can help manage allergic rhinitis, as recommended by the American Academy of Allergy, Asthma, and Immunology 9, 10, 11
• Complete avoidance of animals is the most effective strategy for managing animal allergies, according to the American College of Allergy, Asthma, and Immunology 12
• Addressing non-allergen irritants such as tobacco smoke, strong odors, and temperature/humidity extremes can also help manage symptoms, as suggested by the American Academy of Allergy, Asthma, and Immunology 9, 10

Allergen Immunotherapy

• Allergen immunotherapy can be offered to patients with documented specific IgE antibodies to clinically relevant allergens who fail pharmacotherapy with or without environmental controls, as recommended by the American Academy of Allergy, Asthma, and Immunology 9, 10, 11

Treatment of Allergic Rhinitis

First-Line Treatment

• The American Academy of Allergy, Asthma, and Immunology recommends intranasal corticosteroids as the most effective treatment for controlling all nasal symptoms of moderate to severe allergic rhinitis 13
• Intranasal corticosteroids are superior to all other pharmacological treatments for allergic rhinitis, including oral antihistamines and leukotriene receptor antagonists 13

Treatment for Mild Intermittent Symptoms

• For mild intermittent allergic rhinitis, antihistamines can be used as first-line treatment, with intranasal antihistamines being equal or superior to oral antihistamines of the second generation for seasonal allergic rhinitis 13
• Intranasal antihistamines have a unique advantage of having a clinically significant effect on nasal congestion, unlike oral antihistamines 13

Add-on Therapies

• Ipratropium intranasal is effective in reducing rhinorrhea but has no effect on other nasal symptoms, and its combination with an intranasal corticosteroid is more effective than each agent alone 13
• The American Academy of Allergy, Asthma, and Immunology suggests that ipratropium intranasal can be used as an add-on therapy for patients with persistent rhinorrhea despite treatment with intranasal corticosteroids 13

Immunotherapy

• The American Academy of Allergy, Asthma, and Immunology recommends immunotherapy for patients with inadequate response to pharmacotherapy, as it is the only disease-modifying treatment available 13
• Immunotherapy can prevent the development of new allergen sensitizations and reduce the future risk of asthma 13

Management of Allergic Rhinitis

First-Line Treatment Approach

• The American Academy of Allergy, Asthma, and Immunology recommends intranasal corticosteroids, such as Flonase, as the most effective single medication class for controlling symptoms of allergic rhinitis, including sneezing, itching, rhinorrhea, and nasal congestion, in patients with moderate to severe allergic rhinitis 14
• The American Academy of Allergy, Asthma, and Immunology suggests that Flonase is superior to oral antihistamines in controlling symptoms of allergic rhinitis, with a strength of evidence rated as high 14

Treatment Dosing and Administration

• The recommended dose of Flonase is 200 mcg once daily, administered as 2 sprays per nostril, with maximum efficacy requiring several days of consistent daily use, as stated by the American Academy of Allergy, Asthma, and Immunology 14
• The American Academy of Allergy, Asthma, and Immunology recommends starting Flonase before the pollen season begins for optimal prophylaxis in patients with seasonal allergic rhinitis 14

Combination Therapy

• The American Academy of Allergy, Asthma, and Immunology states that combination therapy with Flonase and cetirizine has not always been shown to provide a major therapeutic advantage that outweighs the cost, with a strength of evidence rated as moderate 15
• The American Academy of Allergy, Asthma, and Immunology recommends adding cetirizine 10 mg daily to Flonase if nasal itching and sneezing remain problematic or if eye symptoms are present, with a strength of evidence rated as high 14

Avoiding Ineffective Treatments

• The American Academy of Allergy, Asthma, and Immunology advises against using first-generation antihistamines, such as diphenhydramine, due to sedation, performance impairment, and anticholinergic effects, with a strength of evidence rated as high 14
• The American Academy of Allergy, Asthma, and Immunology recommends limiting topical decongestants, such as Afrin, to a maximum of 3-5 days to prevent rebound congestion, with a strength of evidence rated as moderate 14

Adjunctive Therapies

• The American Academy of Allergy, Asthma, and Immunology suggests considering oral decongestants, such as pseudoephedrine, for severe nasal congestion, but screening for hypertension, anxiety, or cardiac conditions first, with a strength of evidence rated as low 14

Environmental Control Measures

• The American Academy of Allergy, Asthma, and Immunology recommends identifying specific allergen triggers through skin testing or specific IgE testing, with a strength of evidence rated as high 16

Special Considerations

• The American Academy of Allergy, Asthma, and Immunology states that continuous daily treatment is more effective than intermittent use for perennial allergic rhinitis, with a strength of evidence rated as moderate 14
• The American Academy of Allergy, Asthma, and Immunology recommends monitoring for asthma, as allergic rhinitis increases asthma risk, and treating rhinitis may improve asthma control, with a strength of evidence rated as high 17

Evidence‑Based Management of Allergic Rhinitis

Diagnosis and Initial Assessment

• Intranasal corticosteroids are recommended as the first‑line treatment for patients with moderate‑to‑severe allergic rhinitis whose symptoms impair quality of life, because they provide superior control of nasal congestion, rhinorrhea, sneezing, and itching compared with all other medication classes. – American Academy of Otolaryngology‑Head and Neck Surgery 18
• Clinical diagnosis should be based on a focused history (e.g., nasal congestion, runny nose, itchy nose, sneezing) and physical examination findings such as clear rhinorrhea, pale nasal mucosa, and red watery eyes. – American Academy of Otolaryngology‑Head and Neck Surgery 18
• Routine sinonasal imaging is not indicated for patients whose presentation is consistent with allergic rhinitis. – American Academy of Otolaryngology‑Head and Neck Surgery 18
• A comprehensive assessment must document comorbid conditions—including asthma, atopic dermatitis, sleep‑disordered breathing, allergic conjunctivitis, rhinosinusitis, and otitis media—because these comorbidities significantly influence management decisions and outcomes. – American Academy of Otolaryngology‑Head and Neck Surgery 18
• Specific IgE testing (skin prick or serum IgE) should be performed or referred for when empiric therapy fails, when the diagnosis is uncertain, or when identification of the culprit allergen is needed to target avoidance or immunotherapy. – American Academy of Otolaryngology‑Head and Neck Surgery 18

First‑Line Pharmacotherapy

• For patients with mild intermittent allergic rhinitis whose predominant complaints are sneezing and itching, oral second‑generation antihistamines (e.g., cetirizine, loratadine, fexofenadine) are the recommended initial therapy. – American Academy of Otolaryngology‑Head and Neck Surgery 18

Second‑Line Pharmacotherapy

• Oral leukotriene receptor antagonists (e.g., montelukast) should not be used as primary therapy, nor added to intranasal corticosteroids, because high‑quality trials have shown no additional clinical benefit. – American Academy of Otolaryngology‑Head and Neck Surgery 18

Environmental Control Measures

• Patients with identified allergen sensitivities should be counseled to avoid those allergens and to implement environmental controls such as pet removal, use of high‑efficiency air filtration, allergen‑impermeable bedding covers, and acaricide treatments. – American Academy of Otolaryngology‑Head and Neck Surgery 18

Immunotherapy

• Allergen immunotherapy (sublingual or subcutaneous) should be offered or referred for patients who have an inadequate response to pharmacologic therapy and/or environmental control measures. – American Academy of Otolaryngology‑Head and Neck Surgery 18

Surgical and Procedural Options

• Inferior turbinate reduction may be offered or referred for patients with persistent nasal airway obstruction and enlarged inferior turbinates who have failed optimal medical management. – American Academy of Otolaryngology‑Head and Neck Surgery 18
• Acupuncture can be offered as an optional non‑pharmacologic therapy for patients who express interest in complementary approaches. – American Academy of Otolaryngology‑Head and Neck Surgery 18